Personalised tumor vaccines keep cancer in check
Notable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T-cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies. This creates the need for effective means of expanding the T-cells in patients using cancer vaccines, which will be further explored by MSD, Exicure, Genentech and INSERM.
There has been substantial progress made in these fields and It's time to connect these fields to enable the linking of genetic alterations with the type of immune response. SMi's 6th annual Cancer Vaccines conference will host high level cancer geneticists, cancer biologists, experts in cancer antigen, tumor immunologists and vaccinologists, to discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigens and T-cell biology might enable development of next-generation novel therapies for patients with cancer.
With the increasing use of various immunotherapy strategies in the clinic, it is essential for immunomonitoring techniques to be conducted to follow the response of patients to therapy. Such investigations will enable the discovery of neoantigens that may contribute to the efficacy of treatment. The potential cellular players, the use of screening techniques to monitor effects of treatment and an account of an immunotherapy trial will illustrate what is possible in clinical practice.
Running alongside the conference will an exclusive pre-conference workshop held on Tuesday 26th September 2017.
The Biomarkers of immune response workshop is aimed at both clinical and research investigators to give insights into how to develop tools for both developing new therapeutic strategies and how to monitor responses to treatment. This will enable you to design clinical trials and to set up laboratory investigations to evaluate response to immunotherapy.
Rose-Ann Padua, Research Director, INSERM
Antoine Toubert, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM
Eric Tartour, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou
Sharam Kordasti, Senior Lecturer, Kings College London
Zwi Berneman, Professor of Haematology, University of Antwerp
Cancer Vaccines 2017 is proudly sponsored by Northwest Biotherapeutics
6th annual Cancer Vaccines
27th – 28th September 2017
Contact e-mail: firstname.lastname@example.org
Contact tel: +44 (0) 207 827 6012
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
1 Westminster Bridge Road
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Personalised tumor vaccines keep cancer in check here
News-ID: 677523 • Views: 306
More Releases from SMi Group
Pharma Microbiology UK Conference to discuss Environmental Monitoring
SMi Reports: The Pharmaceutical Microbiology UK conference, taking place on 20 and 21 January 2020 in London, will include a variety of innovative presentations from the environmental monitoring field. With the slowdown in world economic growth, the Pharmaceutical & Biotechnology Environmental Monitoring industry has suffered a certain impact. However, it has still maintained a relatively optimistic growth over the past four years, as the market size maintained an annual growth rate
Exclusive platform updates on the ASCOD, AJAX, Challenger 2, Warrior IFV, PATRIA …
SMi Reports: Senior experts to present exclusive communication and systems updates at the Future Armoured Vehicles Situational Conference in London, next April SMi Group’s 5th Annual Future Armoured Vehicles Situational Awareness will commence on the 1st and 2nd April 2020, in London. The conference will delve deeper into the role of industry, inviting technical leads, platform managers and programme directors to share their insights on the latest systems and sub-systems, providing
Registration Opens for Future Armoured Vehicles Situational Awareness 2020 in Lo …
SMi reports: The agenda has been released for the upcoming Future Armoured Vehicles Situational Awareness Conference, taking place in London in April 2020. In an increasingly complex and congested digital battlespace, the need to provide near real-time information on the whereabouts of an adversary’s location and intent, using enhanced situational awareness capabilities, is vital in aiding armoured units to respond quickly to incoming threats. It is therefore imperative for defence forces
Registration opens for Smart Water Systems Conference 2020
SMi Reports: Registration now available for SMi’s 9th Annual Smart Water Systems, in London. SMi Group is proud to announce the 9th Annual Smart Water Systems Conference which will take place on 20th – 21st April 2020, in London, UK. The two-day event will offer updates on current projects through case studies from water utility companies such as Anglian Water, De Watergroep, SES Water, DWR Cymru Welsh Water, Thames Water and
More Releases for INSERM
MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conferenc …
SMi Reports: Industry leaders MHRA, Pfizer, Autolus, Tusk Therapeutics, KCL, Boehringer Ingelheim and more are amongst the latest organisations to register for Immuno-Oncology 2018 (http://www.immuno-oncology-conference.com/openpr) There’s just 2 weeks until SMi’s Immuno-Oncology conference commences in London on the 26th and 27th September. With limited places left, interested attendees are urged to book soon to avoid missing out on joining an international gathering of immuno-therapy experts at this highly-anticipated conference. Recent Confirmed Attendees
Nektar Therapeutics, Senior Vice President of Biology and Preclinical Developmen …
SMi Group has announced that Johnathan Zalevsky, Senior Vice President Biology & Preclinical Development, Nektar Therapeutics will be chairing day two of the 6th annual Cancer Vaccines conference, which will be taking place on September 27th & 28th 2017. Johnathan is an immunologist, responsible for the research portfolio at Nektar. Possessing extensive experience on the understanding of cellular and humoral immunity as it relates to vaccination technology and the purpose
Parkinson's Vaccine – Top Experts Unite in European Consortium
EU support boosts development of therapeutic vaccines against Parkinson's and Multiple System Atrophy. AFFiRiS leads consortium. An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance the development of two therapeutic vaccine candidates in parallel.
SMi Group announce Cell-Based Assays conference, 3rd & 4th October 2011
SMi Group is delighted to announce their Cell-Based Assays conference, which will be held on the 21st and 22ndNovember 2011 in London. Over the years, SMi has built a reputation as the leading producer of events relating to Cell-Based Assays in Europe. Now in its 4th year, the event has continued to evolve in response to the demands of our delegates and the pharmaceutical industry marketplace. The event will consist of
Bright Cluster Manager chosen for TOP500-class HPC Cluster in France
Consortium led by the University of Bordeaux 1 and including leading universities, research institutes in southwest France purchase 3,168-core supercomputer comprising technology from Dell, Intel and Bright Computing San Jose, California — Bright Computing, a leader in cluster management software, announced today that the company has been selected to provide the cluster management solution for a French research consortium’s new supercomputer. The HPC cluster, to be installed by ClusterVision at
Riccardo Perfetti, VP from Sanofi-Aventis to speak at Diabetes Summit March 7-8, …
Philadelphia, PA – Riccardo Perfetti, MD, PhD, Vice President, Global Medical Affairs, Diabetes Division at Sanofi-Aventis to give a keynote presentation at GTCbio’s Diabetes Summit taking place on March 7-8, 2011 in Philadelphia, PA. Dr. Perfetti will present “The Regulatory Approval of Glucose-Lowering Agents - An Evolving Landscape”. Dr. Perfetti will discuss the significant changes in the medical management of diabetes. New drugs and new mechanisms of action have been proposed